Prostate Cancer
Conditions
Brief summary
This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, 3) the availability of chemotherapy such as cabazitaxel that can improve survival in subjects with advanced disease and 4) that chemotherapy (docetaxel) given concomitant with hormone treatment has proven to prolong time to progression. It is the investigators hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment. This trial will determine whether any benefit is gained by adding chemotherapy before hormonal therapy to hormonal therapy alone in the population of subjects with metastatic or high risk disease.
Detailed description
This clinical trial is designed on the basis of an unmet clinical need, as well as other factors including: 1) the ability to identify subjects at high risk of dying early from their disease, 2) the fact that hormonal therapy has already been shown to improve survival when applied early in the natural history, 3) the availability of chemotherapy such as cabazitaxel that can improve survival in subjects with advanced disease and 4) that chemotherapy (docetaxel) given concomitant with hormone treatment has proven to prolong time to progression. It is the investigators hypothesis that a more appropriate group of patients who may benefit from the curative potential of systemic chemo-hormonal modality is that with minimal, but detectable disease who have a high probability of developing metastatic disease, clinical symptoms and eventually death from prostate cancer in a defined time frame. The investigators hypothesize further that the approach is likely to be more effective at a time of minimal tumour burden, resulting in minimization of the overall burden of therapy and better quality of life while on treatment. This trial will determine whether any benefit is gained by adding chemotherapy before hormonal therapy to hormonal therapy alone in the population of subjects with metastatic or high risk disease. Two therapeutic approaches will be compared in this two-arm randomized clinical trial. The control Arm A provides hormonal therapy alone. The experimental Arm B involves treatment with hormone therapy + Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable or responding disease up to 10 cycles. For the schematic representation of study design please see Section 7.3.1. Subjects with primary metastatic or N+ or high risk disease (PSA\>100) will be eligible. The primary endpoint of the trial is overall survival. Based on the yearly number of prostate cancer patients who are diagnosed with metastatic or high risk disease, approximately 1200 men per year (if +15% improvement)are potential candidates for this approach in the Scandinavian countries .
Interventions
DRUGCabazitaxel + Androgen deprivation therapy
Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
DRUGAndrogen deprivation therapy
LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Sponsors
Örebro University, Sweden
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological confirmed prostate adenocarcinoma Metastatic PC (Prostate cancer) with measurable or evaluable disease or High risk PC (PSA \> 100) or Node positive disease (N+) * No prior treatment for prostate cancer (including bisfosfonate) * Age above 18 years * ECOG 0- 2 * Estimated survival \> 3 months * WBC 2000 / mm 3, neutrophils ≥1500 / mm 3, platelets 100,000 / mm 3 * Satisfactory liver function: bilirubin, transaminases ≤ 1.5 times the upper limit of normal. * Satisfactory renal function. Serum creatinine \<1.5 x ULN (150 mmol/l). If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \>60 mL/min are accepted in the study. https://www.qxmd.com/calculate-online/nephrology/ckd-epi-egfr * Patient information and signature of informed consent
Exclusion criteria
* Cardiovascular disease (severe symptomatic coronary artery disease, congenital heart failure, class 3 and 4 of the NYHA) * Severe peripheral neuropathy * Active infection or other serious underlying pathology that could prevent patients from receiving treatment * History of cancer within 5 years before inclusion in the study other than basal cell or squamous cell skin cancer adequately treated * Brain metastases, uncontrolled symptomatic or asymptomatic * Patient participating in another clinical trial protocol with a molecule during this experimental study or treated four weeks prior to randomization. * Concurrent or planned treatment with potent inhibitors or inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B) * Systemic treatment with high dose steroids * Any severe acute or chronic medical condition which would impair the ability of the patient to participate to the study or interfere with interpretation of study results, or patient unable to comply with the study procedures. * History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | From date of randomization until date of death from any cause, assessed up to 7 years. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | From date of randomization until progression, assessed up to 3 years. | Ct and bonescan at three and six months and then at progession. PSA assesments every three moths during the first year and then every six months until progression. |
| PSA response | From date of randomization up to 7 years. | Assements every three months during the first year. Then every six months until progression. Then after progression every 12 months. |
Countries
Sweden
Outcome results
None listed